TSE:4503Pharmaceuticals
Astellas Licenses Dyno Muscle Gene Therapy Capsid And Investors Weigh Upside
Astellas Pharma (TSE:4503) licensed a novel AAV capsid from Dyno Therapeutics, designed for targeted gene therapy delivery to skeletal muscle.
This is the first capsid licensed under the Astellas and Dyno collaboration and Dyno's first licensed muscle targeting capsid.
The agreement focuses on improving gene therapy delivery and manufacturing efficiency for Astellas's programs.
Astellas Pharma, a global pharmaceutical company listed on TSE:4503, has been building out its gene therapy...